Kinnate Biopharma Stock Rating Lowered by Piper Sandler
About 67% of Kinnate Biopharma's investor base is looking to short. The analysis of current outlook of investing in Kinnate Biopharma suggests that many traders are alarmed regarding Kinnate Biopharma's prospects. The current market sentiment, together with Kinnate Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Kinnate Biopharma stock news signals to limit their universe of possible portfolio assets.
Kinnate |
Kinnate Biopharma was downgraded by equities researchers at Piper Sandler from an overweight rating to a neutral rating in a note issued to investors on Tuesday, MarketBeat reports. They currently have a 4.00 price target on the stock, down from their prior price target of 20.00. Piper Sandlers price target
Read at thelincolnianonline.com
![]() |
Kinnate Biopharma Fundamental Analysis
We analyze Kinnate Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kinnate Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kinnate Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Kinnate Biopharma is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Kinnate Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kinnate Biopharma stock to make a market-neutral strategy. Peer analysis of Kinnate Biopharma could also be used in its relative valuation, which is a method of valuing Kinnate Biopharma by comparing valuation metrics with similar companies.
Peers
Kinnate Biopharma Related Equities
PASG | Passage Bio | 7.65 | ||||
GLUE | Monte Rosa | 7.53 | ||||
STOK | Stoke Therapeutics | 4.86 | ||||
DSGN | Design Therapeutics | 3.30 | ||||
BOLT | Bolt Biotherapeutics | 2.78 | ||||
IPSC | Century Therapeutics | 1.92 | ||||
ERAS | Erasca | 0.00 | ||||
CCCC | C4 Therapeutics | 0.00 | ||||
LRMR | Larimar Therapeutics | 0.00 | ||||
EWTX | Edgewise Therapeutics | 0.82 | ||||
KZR | Kezar Life | 0.97 | ||||
PALI | Palisade Bio | 1.32 | ||||
KRON | Kronos Bio | 1.38 | ||||
SLRN | ACELYRIN, INC | 1.63 | ||||
KROS | Keros Therapeutics | 2.43 | ||||
SRZN | Surrozen | 2.76 | ||||
WINT | Windtree Therapeutics | 3.11 | ||||
GBIO | Generation Bio | 7.10 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |